What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Rury R. Holman mainly focuses on Diabetes mellitus, Internal medicine, Type 2 diabetes, Surgery and Endocrinology.
The various areas that Rury R. Holman examines in his Diabetes mellitus study include Prospective cohort study, Intensive care medicine, Cumulative incidence and Risk factor.
His Cardiology research extends to Internal medicine, which is thematically connected.
The concepts of his Type 2 diabetes study are interwoven with issues in Metformin, Rosiglitazone and Glycemic.
His Surgery research is multidisciplinary, relying on both Heart failure, Semaglutide, Confidence interval, Stroke and Placebo.
His work on Hypoglycemia as part of general Endocrinology research is frequently linked to Association, bridging the gap between disciplines.
His most cited work include:
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (14520 citations)
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (7723 citations)
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (6484 citations)
What are the main themes of his work throughout his whole career to date?
Rury R. Holman spends much of his time researching Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Insulin.
Internal medicine is closely attributed to Cardiology in his research.
His biological study spans a wide range of topics, including Surgery, Blood pressure, Disease and Risk factor.
His work on Sitagliptin and United Kingdom Prospective Diabetes Study as part of general Type 2 diabetes study is frequently linked to In patient, bridging the gap between disciplines.
His studies in Impaired glucose tolerance integrate themes in fields like Valsartan and Nateglinide.
His Myocardial infarction research includes themes of Stroke and Heart failure.
He most often published in these fields:
- Internal medicine (70.94%)
- Diabetes mellitus (50.39%)
- Type 2 diabetes (40.80%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (70.94%)
- Type 2 diabetes (40.80%)
- Diabetes mellitus (50.39%)
In recent papers he was focusing on the following fields of study:
Rury R. Holman focuses on Internal medicine, Type 2 diabetes, Diabetes mellitus, Exenatide and Randomized controlled trial.
His Internal medicine study integrates concerns from other disciplines, such as Type 2 Diabetes Mellitus and Cardiology.
The Type 2 diabetes study combines topics in areas such as Metformin, Proportional hazards model, Emergency medicine and Hazard ratio.
His Diabetes mellitus research is multidisciplinary, incorporating perspectives in Incidence, MEDLINE, Placebo, Disease and Prospective cohort study.
His work in Exenatide tackles topics such as Family medicine which are related to areas like Cardiovascular outcomes.
His Randomized controlled trial research incorporates themes from Research design, Meta-analysis, Nateglinide, Glycemic and Physical therapy.
Between 2017 and 2021, his most popular works were:
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (555 citations)
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (196 citations)
- Real-world studies no substitute for RCTs in establishing efficacy (43 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His primary areas of investigation include Internal medicine, Type 2 diabetes, Diabetes mellitus, Placebo and Hazard ratio.
His research integrates issues of Exenatide and Type 2 Diabetes Mellitus in his study of Internal medicine.
His Type 2 diabetes research includes themes of Metformin, Glycemic, Myocardial infarction and Risk factor.
His study in Diabetes mellitus is interdisciplinary in nature, drawing from both Prospective cohort study, Discontinuation and Pharmaceutical industry.
The study incorporates disciplines such as Cardiovascular outcomes, Proportional hazards model and Urology in addition to Placebo.
His Blood pressure research focuses on Relative risk and how it connects with Surgery and Complication.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
